Member Info for Phantom25

Research use of the labs although welcome is chicken feed compared to something like a possible deal with Solaris for example, for clinical services. Research studies and trials are typically under 200 patients, Solaris treat 750k patients per year. For that reason when I concider contracts, I'm only really thinking of clinical. I don't think the odd research study is going to shift the SP much

My understanding was that until the labs are accredited that they can only be used for study and research use, and accreditation is required to provide direct clinical services for patients. Are you saying that is incorrect

From FDA.gov CLIA page
Diagnostic testing helps health care providers screen for or monitor specific diseases or conditions. It also helps assess patient health to make clinical decisions for patient care. The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.

https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clinical-laboratory-improvement-amendments-clia

Researcher, a bit hypocritical of you complaining that AN sold some of his shares(not all), when you sold the majority of yours immediately after FDA.
Contract deals are a 2 way negotiation, you can't just make them appear. And no one is going to sign a lab deal until CLIA is complete(a decision in the hands of a third party, not Angle). If you read the statement of corporate governance you will see that the BOD of non executive directors are not encouraged to have anything other than a minor share holding for reasons of holding an Independent status. How do you know that negotiations are not underway, but AN is not rolling over to the first crap offer. If I felt like yourself having no faith in the company, I'd sell up and move on.
AN did not say he only wanted rich holders, he said he was not interested in short term traders.

How are you bewildered by the strategy. Explain in detail what you would have done differently

Yes, a basic education is not one of FTM's strong points.

I actually believe there are situations where showing buys and sells make things worse. Wildebeest, sheep and lemmings come to mind, I don't know why I'm running, but everyone else is. I don't know why I'm selling but everyone else is

It's not really an antiquated system, it's the way electronic trading works. You have bought some shares, but that means someone else has sold some shares, in the case of AGL that someone else is always a MM. London SE does not distinguish between buy/sell it just views it as a share transfer. If you trade shares on the main exchange with larger companies most trades are order driven(SETS) and you are literally exchanging shares with another peer. It's like you selling a car on Auto trader, is it a buy or a sell? It's both. The problem you describe is brought about by sites like this that try and estimate a trade from investors/MM perspective and they can only guess.

I think his short isn't turning out how he'd hoped

https://youtu.be/ReivU5J3rSE

Yes. And just a hint for you, L2 has little use on shares that are not traded on the SETS system this includes AVACTA and most other AIM shares. L2 primary use is on larger shares on the main exchange, and it allows you to see the number of buy/sell orders and their value

Hopefully not, cash to mid 2024 if I remember correctly.

No, manufacturing is outsourced

CLS did say they intend to buy and hold, so they could buy gently, spread it over a couple of months or more

I did think the same, but think Angle would want close to 80p, the last issue price

Dark pools don't apply to small cap AIM shares, plus because AGL isn't traded on a SETs visible book there is no need. They can buy without being visible via MMs. Also when CLSC published their decision to include AGL in the portfolio the SP was circa 80p, so doubt they would worry about the SP drifting up a bit, they are long term holders not traders

Yes Dibs I was referring to the IPO by Conviction Life Sciences

Also on ADVFN if we're referring to the same thing

Well the CEO thinks it's worth a punt , he just bought 435,000

I think one of the uses for Parsortix that doesn't get mentioned a great deal, is not how to treat the patient but to choose when not to treat a patient. An example, my father was diagnosed with no Hodgkin's lymphoma. A decesion was made to leave it untreated and wait. He was monitored every 3 months. But the monitoring was very basic, an interview, measuring the lymph nodes by feel and basic bloods. This carried on for 5 years. I am not sure if NHL is detected by Parsortix, but if it could be it would be a strong tool in the sit, wait and monitor scenario

Dunk I can't understand what you require to believe that Parsortix can capture live CTC clusters. You have been given a statement from Angle and a peer reviewed study publication from the Bazel university in Switzerland, but continue to believe a sales document from Datar that states cell cluster retrieval in other devices is "anecdotal". Also the Datar system exposes the cells to a heat process and exposure to, (as far as I can understand) antibodies. So the cells can no longer be considered virgin cells. How does anyone know if the Datar process doesn't alter the characteristics of the CTCs from a downstream analysis perspective